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Conclusions
• Study of the known genes and risk factors. More
investigation about these genes’ influence mechanisms
should be carried out in order to improve prevention,
diagnosis and design new treatments.
• Study of the unknown genes and risk factors. Only 30-50%
of EOAD cases are caused by identified mutations, and only
20% of the LOAD risk is explained by known factors. More
investigation should be carried out to identify more genes
and risk factors related to Alzheimer’s Disease. That would
also allow improvement in prevention, diagnosis and
would open the door to new treatment strategies.
Introduction
• Neurodegenerative disease.
• Most frequent cause of dementia: it represents 66% of all dementias1
• High prevalence: 13% of the population over 65 and 45% of population over 85 years old.
• 2 types and different genes related (figure 1)
• Diagnosis: family history + psychic and cognitive tests + magnetic resonance (to rule 
out other dementia causes)
• Risk factors. Genetic factors and age.
• Molecular features. Presence of:
• Senile plaques: extracellular β – amyloid deposits (Aβ)
• Neurofibrillary tangles: intraneuronal tau protein aggregates
• Treatment. Without treatment, but several strategies have been tested:
• Facilitate Aβ clearance + prevent Aβ aggregation4
• Inhibit or modulate γ – secretasa complex activity5
• Modulate apoE function6
Figure 1. Types of Alzheimer’s Disease and their main features
Genes related to Early Onset Alzheimer’s Disease (EOAD)
Amyloid Precursor Protein (APP)
Steps:
The two major Aβ forms are Aβ40 (under normal conditions it represents 90% of Aβ
8) and
Aβ42. The different forms have different aggregation properties: Aβ40 aggregates less than
Aβ42, Aβ43 and Aβ38 forms
5.
During the processing the C terminus, which is hydrophobic, is shortened, such that the
shorter the fragments the easier they are to release.
Mutations and its effect on Alzheimer’s Disease
In APP, 24 pathogenic, 1 of unclear pathogenicity, 1 protective and 5 non-pathogenic point
mutations have been described. They cause 15% of all Early Onset Alzheimer’s Disease
cases. They affect through different pathways3:
• Aβ production modulation: the mutations map in the β – secretase and γ – secretase
cleavage area.
• Change of the preferred cleavage position at site ε: there is a preference for the Aβ48
production line.
• More efficient folding  faster aggregation. The mutations map in all the sequence of
exons 16 and 17.
Additionally, 9 APP duplications have been described. They affect the APP dosage.
Presenilins (PSEN1 and PSEN2)
PSEN1 is located at 14q24.3 and PSEN2 at 1q42.13. They code for the catalytic subunit of
the γ – secretase complex. PSEN1 has 9 transmembranal domains (figure 4). The active
site is located between the domains 6 and 79.
Effects5,10
• Change of the preferred cleavage position at site ε. There is a preference for the
position 48. It can be due to a missense mutation that changes PSEN1 conformation
and, therefore, there is an APP differential binding. In some cases, it can be caused by
insertions or deletions.
• Changes in processing efficiency. There is a reduction: the Aβ49  Aβ40 processing
efficiency is 2-9% compared to the wild type protein and the Aβ48  Aβ42 processing
efficiency is 17-40% compared to the wild type.
• Proteolysis inhibition at site ε. The mutations reduce PSEN stability.
• 4th cleavage efficiency reduction. The mutations cause conformational changes in the
active site and a premature release of Aβ42 and Aβ43 peptides.
The γ – secretasa complex
It comprises 4 subunits.
• Presenilin
• Nicastrin
• APH – 1
• Pen – 2
Mutations
In PSEN1, 185 pathogenic, 1 of unclear pathogenicity and
4 non-pathogenic point mutations have been described.
They cause 18-50% of all Early Onset Alzheimer’s Disease
cases.
In PSEN2, 13 pathogenic, 7 of unclear pathogenicity and
5 non-pathogenic point mutations have been described.
It is located at 21q21.2 and codes for a
protein called APP (figure 2). APP
undergoes a proteolytic processing that
results in Aβ formation (figure 3).
Figure 2. APP structure. From Van Broeck, et al7.
Figure 4. Presenilin strucure. Adapted from
Wolfe, M. S.9
Figure 3. Different pathways of the APP processing
Genes related to Late Onset Alzheimer’s Disease (LOAD)
APOE
It is located at 19q13.2 and codes for apoE protein. Its more important functions are lipid and Aβ transportation, cellular metabolism regulation and
participation in the reparation of neuronal injuries caused by oxidative stress. It has 3 common variants (apoE2, apoE3 and apoE4) that differ in the
amino acids of the positions 112 and 158 (figure 5). These variations affect apoE structure and its capacity to bind Aβ, among other effects12.
The ε4 allele is a risk factor: its frequency among affected individuals is 40 – 50%,
whilst in the general population it is 13.7% (figure 6).
Aβ levels and senile plaques charge depend on the allele. The risk depends on the genotype: 91% of ε4/ε4 individuals and 47%
of ε4/ε- individuals, but only 20% of ε4 non-carrier individuals are affected (figure 7)13.
Effects6,11
• Clearance of Aβ. Different ways: absorption and cellular degradation, transport across the blood – brain barrier or enzymatic
degradation. The apoE4 – Aβ union is less efficient than apoE2/3 – Aβ union.
• Aggregation promotion. apoE and Aβ coaggregate. apoE4 might stabilize Aβ oligomers more than apoE3/2.
• Differential regulation of cholesterol levels  the cholesterol regulates the γ – secretase complex.
• Other mechanisms. Tau phosphorylation, synaptic function regulation, neuroinflammation and neurogenesis.
Figure 5. apoE structure. Adapted from Kanekiyo, T.,
Xu, H., Bu, G.11.
Figure 7. Risk of developing Alzheimer depending on age
and genotype. From Spinney, L.13
Figure 6. APOE variant distribution
in general population
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